This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary VEGFR Therapeutic Antibody Development
Background of VEGFR
In the tumor microenvironment, excessive activation of VEGFRs can promote tumor cell growth by increasing angiogenesis, providing more nutrients and oxygen, thereby accelerating their proliferation and spread. Inhibiting the activation of this pathway has become a crucial strategy in companion animal cancer treatment. BioVenic has established a platform for developing veterinary VEGFR therapeutic antibodies, providing a comprehensive range of services covering the entire antibody development process to explore its potential in treating companion animal cancers.
Background of VEGFR
| Full Name | Vascular endothelial growth factor receptor |
|---|---|
| Aliases | FLK1, KDR, CD309. |
| Target Profile | VEGFRs are a group of transmembrane receptor tyrosine kinases that regulate angiogenesis, essential for tissue growth and repair. There are three primary types: VEGFR-1, VEGFR-2, and VEGFR-3. Members of the VEGF family stimulate cellular responses by binding to VEGFRs on the cell surface, regulating the formation and repair of blood vessels. |
MoA of VEGFR
Upon activation, VEGFRs stimulate gene expression through the Ras/MEK/ERK signaling pathway, promoting cell proliferation. VEGFRs also activate PLC-γ, which generates PKC, increasing intracellular calcium levels, and then enhancing vascular permeability. Additionally, VEGFRs promote cell migration by renewing focal adhesions and activating proteins related to cell movement through the FAK pathway. HSP27 activation through the p38 signaling pathway promotes actin reorganization, further facilitating cell migration. Another key pathway is the PI3K pathway, which maintains cell survival by catalyzing the transformation of PIP2 to PIP3. PIP3 recruits Akt to the cell membrane, which boosts cell survival by inhibiting pro-apoptotic proteins like caspase 9 and BAD. The combined actions of these signaling pathways are crucial in promoting cell proliferation, migration, survival, and increasing vascular permeability, thus facilitating angiogenesis, and significantly impacting tumor growth and development.
Fig.1 Schematic diagram of VEGFR signaling in tumor angiogenesis.1
Application in Veterinary Therapeutics
VEGFR is expressed in various companion animal tumors, including canine mast cell tumors, anal sac adenocarcinoma, T-cell lymphoma, nasal carcinoma, cutaneous squamous cell carcinoma, hair follicle tumors, and feline mammary tumors. Targeting and inhibiting VEGFR offers the potential to effectively block tumor angiogenesis, thereby suppressing tumor growth and metastasis.
Veterinary VEGFR Therapeutic Antibody Development Services
The abnormal expression or dysfunction of VEGFR is closely related to the development of multiple cancers in companion animals. BioVenic provides veterinary VEGFR therapeutic antibody development services. We not only ensure the high-quality design and precise production of antibodies but also conduct in-depth purification and characterization. Additionally, our team focuses on providing customized antibody development solutions for different animal species to minimize immunogenicity.
Please click the link below for more information about our veterinary VEGFR therapeutic antibody development services.
Why Choose Us?
BioVenic has established a diverse antibody development platform, including hybridoma technology, single B cell technology, and phage display technology.
Our antibody engineering services include antibody caninization/felinization, affinity maturation, and Fc engineering, aimed at reducing the immunogenicity for specific species, enhancing their affinity, and extending their half-life.
We offer species-specific antibody development services, avoiding safety risks, and enhance the compatibility of antibody samples in companion animals.
With anti-angiogenesis as a treatment strategy for companion animal cancers, VEGFR is a significant target. BioVenic offers veterinary VEGFR therapeutic antibody development services to assist in exploring the therapeutic potential of VEGFR in companion animal cancer treatment. If you have development needs in this area, please contact us now for more information!
References
- Ivy, S. Percy, et al. "An overview of small-molecule inhibitors of VEGFR signaling." Nature reviews Clinical oncology 6.10 (2009): 569-579.
- Gramer, Irina, et al. "Expression of VEGFR and PDGFR‐α/‐β in 187 canine nasal carcinomas." Veterinary and comparative oncology 15.3 (2017): 1041-1050.
- Nascimento, Catarina, et al. "Diagnostic value of VEGF-A, VEGFR-1 and VEGFR-2 in feline mammary carcinoma." Cancers 13.1 (2021): 117.